IDXX Stock Analysis: Buy, Sell, or Hold?
IDXX - Idexx Laboratories Inc
$558.32
-14.97 (-2.61%)
▼
5d:
-3.28%
30d:
-15.5%
90d:
-18.29%
BUY
MODERATE Confidence
Analysis Updated: Mar 27, 2026 12:00 AM ET
Earnings: May 07, 2026
Smart Money Accumulation
IDXX is down 4.7% this week, but smart money is accumulating calls. Top strike: $820 2026-04-17 with 56 OI. Call ratio: 84% View Scanner →
Strength: 5.7/10
Get Alerted When IDXX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: IDXX shows positive signals but monitor for confirmation. Market pricing in 7.8% decline. Moderate conviction.
💡 BUY OPPORTUNITY: IDXX shows positive signals but monitor for confirmation. Market pricing in 7.8% decline. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$614.86
Based on 8.5% avg growth
INTRINSIC VALUE TODAY
$381.78
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 25.0x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: IDXX is currently trading at $558.32, which is considered oversold relative to its 30-day fair value range of $574.82 to $638.54. From a valuation perspective, the stock is trading at a discount (Forward PE: 34.1) compared to its historical average (43.4). Remarkably, the market is currently pricing in an annual earnings decline of 7.8% over the next few years. This pessimistic expectation contrasts with the company's recent 17.9% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, IDXX is in a strong downtrend. The price is currently testing key support at $562.09. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: IDXX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $750.23 (+34.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, IDXX is in a strong downtrend. The price is currently testing key support at $562.09. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: IDXX has a weak technical setup (25/100), with bearish trendlines and momentum suggesting caution for short-term entries. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $750.23 (+34.4%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$574.82 -
$638.54
Company Quality Score
59/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
65.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 0th percentile)
- BEARISH: Weak technical setup (25/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 34.4% below Wall St target ($750.23)
Fair Price Analysis
30-Day Fair Range
$574.82 -
$638.54
Current vs Fair Value
OVERSOLD
Expected Move (7 Days)
±$27.53
(4.9%)
Support & Resistance Levels
Support Level
$562.09
Resistance Level
$599.97
Current Trend
Strong Downtrend
Technical data as of
Mar 27, 2026
Fundamental Context
Forward P/E (Next Year Est.)
34.06
Wall Street Target
$750.23
(+34.4%)
Revenue Growth (YoY)
14.3%
Earnings Growth (YoY)
17.9%
Profit Margin
24.6%
Valuation Discount vs History
-7.8% cheaper
PE vs Historical
34.1 vs 43.4
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-7.8%
(market-implied from PE analysis)
1-Year Target
$514.77
(-8%)
2-Year Target
$474.62
(-15%)
3-Year Target
$437.60
(-22%)
3-Yr Target (if PE normalizes)
(PE: 34→43)
$557.58
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 34.1, Growth: 13.0%)
$804.59
(+44%)
Base:
(SPY PE: 22.4, Growth: 13.0%)
$529.13
(-5%)
Bear:
(PE: 19.0, Growth: 13.0%)
$449.76
(-19%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (44x PE), but valuation improves significantly next year (34x PE) as earnings recover.
Trailing PE: 44.07 | Current EPS (TTM): $13.10
Bull Case
$794.54
(+37%)
Analyst growth 25.1%, PE expands to 48.5
Base Case
$722.31
(+25%)
Market implied 25.1%, PE stable at 44.1
Bear Case
$392.54
(-32%)
Severe decline -20.0%, PE contracts to 37.5
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 34.1 to 43.4
Stabilization Target:
$711.40
(+27.4%)
PE Expansion Potential:
+27.4%
Share & Embed Analysis
Last updated: March 30, 2026 8:52 AM ET
Data refreshes hourly during market hours. Next update: 9:52 AM
Data refreshes hourly during market hours. Next update: 9:52 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IDXX showing a specific setup today?
Insider Activity (6 Months)
2
Buys
11
Sells
Net
INSIDERS SELLING
Recent Transactions
Nimrata Hunt
SELL
1758 shares
2026-03-03
Jonathan Jay Mazelsky
SELL
23326 shares
2026-02-26
Nimrata Hunt
SELL
2693 shares
2026-02-26
Top Rated Diagnostics & Research Stocks
Top-rated stocks in Diagnostics & Research by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
TMO
Thermo Fisher Scientific… |
STRONG BUY
31 analysts |
$664 | 58 HOLD |
|
EXAS
EXACT Sciences Corporati… |
STRONG BUY
26 analysts |
$106 | 65 BUY |
|
DHR
Danaher Corporation |
STRONG BUY
26 analysts |
$265 | 58 HOLD |
|
GH
Guardant Health Inc |
STRONG BUY
24 analysts |
$133 | 56 HOLD |
|
NTRA
Natera Inc |
STRONG BUY
21 analysts |
$261 | 60 HOLD |
Advanced IDXX Option Strategies
Professional options setups generated by AI based on today's IDXX price and gamma walls.
